Sanofi-Aventis settles federal lawsuit for $182.8 million

Share this article:

Sanofi-Aventis agreed to pay $182.8 million plus interest to resolve lawsuits under the federal Claims Act relating to Anzemet and involving predecessor company Aventis Pharmaceuticals.

The US government alleged that Aventis inflated the price for Anzemet, a drug used in conjunction with other cancer treatments, causing the government to overpay for Anzemet for a seven years, between 1997 through 2004.

Anzemet was introduced in 1997 and is provided to cancer patients to prevent nausea and vomiting that can accompany some types of chemotherapy.

Sanofi-Aventis "has decided to resolve this legacy matter through this settlement, without admitting any wrongdoing," the company said in a statement.

Also as part of the settlement deal, Sanofi-Aventis' US pharmaceutical subsidiary
has entered into a five-year corporate integrity agreement with the Office of the Inspector General of the Department of Health and Human Services.

Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...